Introduction
Growth hormone binding protein (GHBP) corresponds to the extracellular domain of the GH receptor (GHR) and is closely related to body fat. 1, 2 The increased fat mass and decreased lean muscle mass associated with hypopituitarism in adults can be improved with GH treatment, and we shown that the reduction in body fat stores with GH replacement in this group results in a reduction in serum leptin. 3 We examined the relationship between GHBP, leptin and body composition in GH-de®cient adults, the response of GHBP to GH replacement in this group and whether baseline GHBP predicts IGF-I response.
Methods
Nineteen adults were studied, mean age 47 y (range 20 ± 69), with hypopituitarism and GH de®ciency (mean IGF-I age related SD score of À2.6 AE 0.3) and were randomly allocated (in double-blind fashion) to either GH (up to 0.25 Uakgaweek in daily subcutaneous doses) or placebo for 3 months before crossover to the opposite treatment arm. GHBP was measured by ligand immunofunctional assay 4 (intraassay CVs 2.9 ± 4.9%), leptin by radioimmunoassay (Linco Research Inc., St Charles, MO, USA), and body composition, by dual energy X-ray absorptiometry (Lunar, DPX-L, Lunar Radiation Corp Co., Madison, WI, USA). The effect of treatment on GHBP was analyzed by two-way analysis of variance (ANOVA) with repeated measures. Baseline plasma leptin, GHBP and baseline percentage body fat were compared using Pearson product moment correlation coef®cients.
Results
The changes in body fat and leptin in response to GH have been reported previously. 3 Baseline plasma leptin showed a signi®cant correlation with baseline BMI, r 0.67, P`0.005 and baseline percentage total body fat, r 0.81, P`0.0001. 3 There was a strong correlation between baseline GHBP and percentage total body fat, r 0.83, P`0.0001, although there was no signi®cant correlation with baseline body mass index, r 0.41, P 0.08. There was a strong correlation between baseline leptin and GHBP, r 0.88, P`0.0001. There was no signi®cant correlation between baseline IGF-I and GHBP, r À0.049, P 0.84. There was no signi®cant correlation between baseline GHBP and change in IGF-I SDS in response to GH replacement, r À0.037. GHBP (mean AE s.e.m.) was signi®cantly (P 0.049) higher on average during the 12 weeks of GH treatment (1.53 AE 0.25 nM) than on placebo (1.41 AE 0.25 nM) (Figure 1 ).
Discussion
We have therefore shown a strong correlation between GHBP and percentage total body fat, and between GHBP and leptin. We have also shown GHBP levels to be increased in response to GH replacement in GHde®cient adults, although that baseline GHBP levels do not predict IGF-I responses. It could be postulated that GHBP attenuates the action of GH, resulting in increased adiposity and leptin. Alternatively, increased adiposity may promote an increase in GHBP (perhaps mediated by leptin). Our ®ndings add support to a role for GHBP in regulation of body composition, rather than a passive by-product of increased cellular expression of GH receptors.
